Sellas Life Sciences Group Inc Quick Ratio (SLS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
SLS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Sellas Life Sciences Group Inc 's Cash & cash equivalent grew by 29.15 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Sellas Life Sciences Group Inc 's Quick Ratio to 17.29 a new company high.
Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Quick Ratio than Sellas Life Sciences Group Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 291, from total ranking in the first quarter 2026 at 547.
SELLAS Life Sciences Group Successfully Closes $20 Million Offering, Accelerating Cancer Therapies Development NEW YORK, March 19, 2024 - Leading biopharmaceutical company, SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), has triumphantly concluded its registered direct offering and concurrent private placement, raising an impressive $20 million. The funds will be allocated towards advancing the development of groundbreaking cancer therapies across a wide spectrum of indications. With a combined purchase price of $1.535 per share, this offering was priced at-the-market under Nasdaq rules to ensure fair and transparent transactions. The Offering included the issuance of 13,029,316 shares of common stock, or common stock equivalents, along with accompanying warrants that enable the purchase of up to 13,029,316 additional shares of common stock. The warrants were priced at $1.41 per share and hold an exercise period of 5.5 years from issuance. Upon receipt, shareholders can immediately exercise the warrants, enhancing their ability to benefit from the promising future prospects of SELLAS Life Sciences Group.
In a significant move for SELLAS Life Sciences Group, Inc., the company has announced that it has entered into definitive agreements with two existing institutional investors for the purchase and sale of over 13 million shares of its common stock in a registered direct offering. Additionally, warrants to purchase up to an aggregate of 13 million shares of common stock will be available in a concurrent private placement. The combined purchase price for the offering is set at $1.535 per share, with accompanying warrants having an exercise price of $1.41 per share. These warrants will be immediately exercisable upon issuance and will expire 5.5 years from issuance. This news comes on the heels of a decrease in SELLAS s Quick Ratio over the past year, despite a decrease in current liabilities. The Quick Ratio, which measures a company s ability to meet its short-term obligations with its most liquid assets, has decreased by 1.06 on a trailing twelve months basis. This is below the company s average Quick Ratio, indicating potential liquidity challenges.
On the trailing twelve months basis SLS Cash & cash equivalent more than doubled by 445.12 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Sellas Life Sciences Group Inc 's Quick Ratio to 13.5, above SLS average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Sellas Life Sciences Group Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2551.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
